Naivek and US Omega Joint Research... "70% Drug Delivery Proven in mRNA New Drug Pipeline"

Naivek announced on the 29th that it has signed a joint research agreement to apply its drug delivery platform ‘NIPEP-TPP’ to the mRNA-based lung cancer treatment and other new drug pipelines of the US biotech company Omega Therapeutics (Omega).

This agreement is highly likely to succeed as it follows Naivek’s confirmation in its own preliminary tests based on the ‘NIPEP-TPP’ technology that more than 70% of the administered drug dose is delivered to the lungs.

Under this agreement, Naivek will develop mRNA nanocomplexes based on the drug delivery platform ‘NIPEP-TPP’ and provide them to Omega. Omega plans to apply this mRNA delivery system to the development of treatments for lung diseases, including lung cancer, which it is developing independently. The two companies will initially collaborate on developing treatments targeting lung diseases and plan to expand the applicable pipelines depending on the results of the contract.

Since last year, Naivek has maintained a collaborative relationship at the joint research level through a Material Transfer Agreement (MTA) with the US company Sarepta Therapeutics (Sarepta) for the development of treatments for muscular dystrophy and muscle diseases. In addition to Sarepta and Omega, Naivek plans to continuously expand the application areas of NIPEP-TPP through joint research with various companies in the future.

NIPEP-TPP is a peptide-based drug delivery platform developed by Naivek. It can selectively deliver various drugs, including protein antibodies and RNA therapeutics, into cells. In particular, it has the advantage of reducing side effects due to its high efficiency in delivering drugs to target cells or tissues.

A Naivek official said, “Peptide-based mRNA delivery systems like NIPEP-TPP are suitable as next-generation high-efficiency drug delivery systems because of their high intracellular drug expression rates,” adding, “Especially since selective delivery to target cells is possible, it can be applied in various fields such as vaccines and anticancer drugs.”

He continued, “Through the joint research agreement with Omega, we will accelerate the development of next-generation lung cancer treatments using high-efficiency mRNA delivery systems,” and added, “Since Omega possesses globally recognized mRNA technology, this agreement will produce mutually beneficial results for both companies.”

Omega Therapeutics is a biotech company developing epigenome-based mRNA therapeutics. Its core pipeline, ‘OTX-2002,’ is an mRNA therapeutic that suppresses MYC gene expression and is currently undergoing clinical trials for hepatocellular carcinoma (HCC) treatment. ‘OTX-2002’ has been designated as an orphan drug by the US Food and Drug Administration (FDA). Omega Therapeutics has been in discussions with Naivek for a long time to apply drug delivery platform technology to its new drug pipeline.

This content was produced with the assistance of AI translation services.